4H-1-Benzopyran-4-one, 7,8-bis[[(methylamino)carbonyl]oxy]-2-phenyl-

TrkB-IN-1 (oral gavage; 7.25 mg/kg, 21.8 mg/kg, 43.6 mg/kg; 3 month) activates TrkB signaling cascade in the hippocampus of 5XFAD mice in a dose-dependent manner in 5XFAD mice, the ratio of p-TrkB/TrkB, p-Akt/Akt and p-ERK/ERK is also increased^[1]. TrkB-IN-1 (oral gavage; 7.25 mg/kg, 21.8 mg/kg, 43.6 mg/kg; 5 days) alleviates Aβ deposition and rescues memory deficits in 5XFAD mice^[1]. TrkB-IN-1 (oral gavage; 36 mg/kg) exhibits ～10.5% oral bioavailability with a C_maxof 129 ng/mL, T_maxof 0.5 h, and T_1/2for oral administration of 3.66 h^[1].